Three new drugs for HIV infection.
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002493:Central Nervous System Diseases / Q000139:chemically induced; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D004244:Dizziness / Q000139:chemically induced; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D063065:Organophosphonates; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000099227:Abacavir
D000225:Adenine; D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D063065:Organophosphonates; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz; C106812:adefovir dipivoxil